#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Irene Nunes Email
VP, Head Global Regulatory Affairs . TG Therapeutics
New York, NY
LocationPrimary Email
How to contact Irene Nunes
Join and see Irene's contact info for free!Current Roles
Employees:
404Revenue:
$152kAbout
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".TG Therapeutics Address
2 Gansevoort StreetNew York, NY
United States